bayer-eyes-16-billion-euros-in-2022-adjusted-ebitda

Bayer eyes 16 billion euros in 2022 adjusted EBITDA

© Reuters. FILE PHOTO: A logo of Bayer is seen next to dark clouds at Cologne Bonn airport© Reuters. FILE PHOTO: A logo of Bayer is seen next to dark clouds at Cologne Bonn airport

FRANKFURT (Reuters) - German drugmaker Bayer (DE:), which acquired seed company Monsanto (NYSE:) this year, said it aimed to increase adjusted core earnings to 16 billion euros ($18.1 billion) in 2022, up from an expected 12.2 billion euros this year.

"We will create substantial value by leveraging our innovation capabilities into growth, improved profitability and a higher cash flow. The recently announced efficiency and structural measures will further support us in these endeavors," Chief Executive Werner Baumann said at the group's capital markets day in London on Wednesday.

The 2022 target does not take into account the effect of currency swings.

Bayer last week announced the sale of a number of businesses, around 12,000 job cuts and 3.3 billion euros ($3.8 billion) in impairments.

Disclaimer: Fusion Media

would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.